Cel­gene joins the heavy­weight part­ner club col­lab­o­rat­ing with Nim­bus

The Nim­bus Ther­a­peu­tics team has a good track record for find­ing the ide­al part­ner.

There was Gilead $GILD on NASH — with a mas­sive $600 mil­lion in up­front and near-term cash — and Genen­tech stepped in to grab rights to an IRAK4 can­cer pro­gram from the com­pu­ta­tion­al chem­istry ex­perts at Nim­bus. And now you can add Cel­gene $CELG, which is ty­ing up with Nim­bus on two new ther­a­peu­tic ap­proach­es for its grow­ing in­flam­ma­tion/im­munol­o­gy pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.